Healthcare | Corporate Finance Advisory

Immucor Goodwill Valuation Analysis

  • Immucor, Inc. (NASDAQ: BLUD) is the market leader in diagnostic products for blood transfusions, with a market value of over $1 billion
  • Pursuant to the adoption of FAS 142, Immucor is required to test its goodwill balances, which total $27 million, for impairment
  • Immucor retained TM Capital to prepare a valuation analysis of each of its global divisions with goodwill balances
  • TM Capital provided Immucor with its opinion that Immucor’s goodwill balances are not currently subject to impairment

Client Testimonial